Patients undergoing cataract surgery will have more intraocular lens options in the next coming few years. One of the newest additions to receive FDA approval are the IC-8 lens, a small aperture lens with the ability to correct up to 1.5 D of astigmatism and give patients some near vision. The other is the SBL-3 lens, a multifocal which has a segmented optic with two power zones much like a bifocal lens. The efficacy of these lenses is promising and more will be known in the next couple of years.
The PANORAMA study showed evidence of improved outcome in patients with moderate to severe diabetic retinopathy without macular edema, receiving injections.
This article discusses a new drug for macular degeneration that may be able to last longer, thereby reducing the number of injections, than the current injections on the market.
Cataract surgery was found to lower risk of developing dementia in older patients at risk of dementia.
The cost of Restasis may have been prohibitive for many patients. Now the FDA approves a generic which should be available at a lower cost to patients.
Patients with proptosis due to chronic thyroid eye disease may qualify for treatment with Teprotumumab (Tepezza). This drug has an FDA indication for thyroid eye disease.
The article describes some of the side effects from COVID-19 vaccination. These are mainly inflammatory conditions with good prognosis if treated appropriately.
Researchers have found subretinal deposits that mimic drusen, found in macular degeneration, in patient with cardiovascular disease. The process by which there’s this accumulation of the substance is thought to be due to poor circulation from hardened blood vessels.
